CADTH negative recommendation could limit treatment options for Canadians with atopic dermatitis
Sanofi denounces a recent recommendation to not reimburse Dupixent™ for the treatment of moderate-to-severe atopic dermatitis (AD).
2018-07-10MMMM DD, YYYY
2015 Nationwide voluntary recall of Allerject®
Information on the October 28, 2015 voluntary recall by sanofi-aventis Canada Inc. of all lots of Allerject® epinephrine auto-injectors.
View more news & announcements
Sanofi Canada in Depth
Are you a Healthcare Professional?
Please register so that you can stay informed about Sanofi products and services.